This Month in Psychopharmacology

Evening-Dosed Stimulant Approved for ADHD

The US Food and Drug Administration (FDA) has approved a novel extended-release formulation of methylphenidate for the treatment of ADHD in patients age 6 and up. One of the major concerns for patients with ADHD is the fluctuations in symptoms throughout the day, with symptom exacerbation commonly seen in the morning, pre-school hours. Ironshore Pharmaceuticals' Jornay PM® is dosed in the evening and utilizes specialized extended release film coating technology that allows for effective drug delivery in the morning as well as throughout the day. This novel extended-release formulation of methylphenidate provides a welcome addition to the armamentarium of treatment options available for patients with ADHD.

More information



For more information on ADHD:

This Month in Psychopharmacology: ADHD